- Created on Monday, 04 August 2014 20:37
- Written by IVN
Washington, DC - Pharmaceutical company Akorn, Inc. has agreed to sell its rights to develop, manufacture, and market the generic injectable tuberculosis drug, rifampin, in order to settle FTC charges that Akorn’s proposed acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would likely be anticompetitive.
The FTC’s proposed settlement with Akorn requires the company to divest its Abbreviated New Drug Application for generic injectable rifampin - which is currently pending before the Food and Drug Administration - to Watson Laboratories, Inc. Akorn proposes to acquire VersaPharm for approximately $324 million, under an agreement dated May 9, 2014.
According to the FTC’s complaint, only VersaPharm and two other firms currently have FDA approval to sell generic injectable rifampin. There are no viable substitutes for rifampin as a course of treatment for tuberculosis. Absent the acquisition, Akorn likely would have entered the market for generic injectable rifampin in the near future, resulting in a significant price reduction for the drug. According to the FTC’s complaint, if Akorn were to consummate its acquisition of VersaPharm, as originally proposed, the combined company would likely forego or delay the introduction of Akorn’s generic injectable rifampin.
Under the proposed consent order, an interim monitor will supervise Akorn to ensure that it provides Watson with any information the FDA requests, assists Watson to obtain FDA approval for the pending ANDA, and provides transitional services so that Watson can develop the ability to manufacture generic injectable rifampin independently.
More information about the market for this drug and the consent agreement can be found in the analysis to aid public comment for this matter on the FTC’s website.
The Commission vote to accept the proposed consent order for public comment was 5-0. The proposed settlement is part of the Commission’s ongoing effort to protect U.S. consumers from higher healthcare-related costs.
The FTC will publish the consent agreement package in the Federal Register shortly. The agreement will be subject to public comment for 30 days, beginning today and continuing through September 3, 2014, after which the Commission will decide whether to make the proposed consent order final. Interested parties can submit written comments electronically or in paper form by following the instructions in the “Supplementary Information” section of the Federal Register notice.